Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering enzymes in-house; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.
Currently, no events have been added to this timeline yet.
Be the first one to add some.
Senior Vice President, CFO
Senior Vice President of R&D
Corporate and Strategic Development
Documentaries, videos and podcasts